ERBB2 and breast carcinoma: Although four pivotal RCTs (HERA, BCIRG-006, NSABP B-31 and NCCTG N9831) established the standard of care of trastuzumab [5–7], efficacy data are scarce in small-tumor, N0/N1mi, HER2 + low-risk breast cancer population.